The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 ...

The immersive 14-minute performance tells the story of a modern-day sculptor who creates a figure of a god. Through passion and craft, she brings her masterpiece to life. A metaphor for Suprema itself ...

In a separate transaction on the same day, Ensign announced that it acquired the real estate and operations of Timber Springs Transitional Care, a 120-bed skilled nursing facility located in Boise, ...

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech ...

“Ligand has been an incredible partner over the past few years, and we look forward to their continued guidance and support as members of the Pelthos board,” commented Scott Plesha, CEO of Pelthos.

VigRX Plus is the result of collaboration between herbal scientists, medical consultants, and nutraceutical engineers.

The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial. The study is ongoing across sites in the United States, the United Kingdom, France, ...

Helsinki, Finland – July 2, 2025 — GlucoModicum, a health technology innovator focused on needle-free glucose monitoring, today announced positive results from its Clinical Performance Study (CPS), ...

Furthermore, as communicated on June 20, 2025 2, OSE Immunotherapeutics introduced the accelerated procedure, so called “on a set day” ( à bref délai), against the same group of shareholders, for a ...

This offering is expected to close on or about July 3, 2025, subject to the satisfaction of customary closing conditions. ArriVent intends to use the net proceeds from the offering, together with its ...

The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates ...

CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and ...